On Tuesday, Myriad Genetics, Inc. (NASDAQ:MYGN)’s shares declined -2.42% to $36.65.
Myriad Genetics, Inc. (MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that it will host an Investor Day in New York City on Sept. 14, 2015.
At the event, members of the Myriad executive management team will discuss the Company’s five-year strategic plan and provide updates on its three strategic imperatives to transition and expand the hereditary cancer market, diversify the product portfolio and increase the international contribution.
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The company’s molecular diagnostic tests are designed to analyze genes expression levels, and proteins to assess an individual’s risk for developing disease later in life; diagnose diseases and determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, counting myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; BRACAnalysis and BART, sequencing tests for hereditary breast and ovarian cancer; BRACAnalysis CDx sequencing test for use as a companion diagnostic in identifying ovarian cancer patients with deleterious suspected deleterious germline; and Tumor BRACAnalysis CDx sequencing test used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors.
Fairchild Semiconductor Intl Inc (NASDAQ:FCS)’s shares dropped -3.09% to $13.18.
Fairchild (FCS), a leading global supplier of high-performance power semiconductor solutions, declared recently that members of senior administration will attend the following investor conferences this quarter:
Citi Global Technology Conference
Wednesday, September 9th held at Hilton New York Hotel in New York, NY
Mark Thompson, Chairman, President and CEO and Dan Janson, Vice President of Investor Relations, will speak
2015 Drexel Hamilton TMT Conference
Thursday, September 10th held at the W Hotel in New York, NY
Dan Janson, Vice President of Investor Relations, will speak
Fairchild Semiconductor International, Inc. designs, develops, manufactures, and markets power analog, power discrete, and non-power semiconductor solutions worldwide. It operates through three segments: Mobile, Computing, Consumer, and Communication (MCCC); Power Conversion, Industrial, and Automotive (PCIA); and Standard Discrete and Standard Linear (SDT). The MCCC segment offers analog components, mixed signal integrated circuits (ICs), and low voltage power metal oxide semiconductor field effect transistors (MOSFETs) for mobile, consumer, computing, and communication applications; signal path products, such as analog and digital switches, USB switches, video filters, and audio amplifiers; and packaging solutions comprise surface mount devices, tiny packages, chip scale packages, and leadless carriers. Its analog products monitor, interpret, and control variable functions comprising light, color, sound, and energy.
At the end of Tuesday ‘s trade, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s shares dipped -2.49% to $60.98.
AMAG Pharmaceuticals, Inc. (AMAG) declared that it has priced its formerly declared underwritten public offering of common stock comprising of 3,150,000 shares at a public offering price of $63.75 per share. Gross proceeds to AMAG from this offering are predictable to be about $201 million. AMAG intends to use the net proceeds from this offering for the expansion and diversification of its product portfolio through the in-license or purchase of additional pharmaceutical products or companies, such as Cord Blood Registry (CBR), to refinance certain existing indebtedness, to pay various fees and expenses incurred in connection with the CBR acquisition and related financing transactions, in addition to for general corporate purposes.
AMAG has granted the underwriters a 30-day option to purchase up to an additional 472,500 shares of common stock offered in the public offering. All of the shares in the offering will be sold by AMAG.
The offering is predictable to close on August 5, 2015, subject to customary closing conditions. Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering. Leerink Partners LLC is acting as lead manager for the offering. Guggenheim Securities, LLC and Raymond James & Associates, Inc. are acting as co-managers for the offering.
AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women with a singleton pregnancy; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the administration of oral mucocitis/stomatiits and various types of oral wounds.
Hindustan Construction Company Ltd (NSE:HCC), ended its Tuesday ‘s trading session with 1.12% gain, and closed at $18.00.
HCC Insurance Holdings, Inc. (HCC) declared its 78th successive quarterly cash dividend.
HCC’s Board of Directors has declared a regular cash dividend of $0.295 per share on the Company’s shares of $1.00 par value common stock. The dividend is payable to stockholders of record on October 1, 2015 and will be paid on or about October 15, 2015.
To the extent the pending merger with Tokio Marine Holdings, Inc. (“Tokio Marine”) is accomplished on or preceding to the close of business on the October 1, 2015 record date, the dividend will not be paid to stockholders. To the extent the pending merger with Tokio Marine is accomplished following the record date, the cash dividend will be paid to stockholders that held the shares at the close of business on the record date regardless of whether the merger is accomplished before or after the payment date for the dividend.
HCC Insurance Holdings, Inc. underwrites non-correlated specialty insurance products worldwide. The company operates in five segments: U.S. Property & Casualty, Professional Liability, Accident & Health, U.S. Surety & Credit, and International. The U.S. Property & Casualty segment provides aviation, primary and excess casualty, small account errors and omissions (E&O) liability, employment practices liability (EPLI), disability, contingency, public risk, technical and construction property, title and mortgage reinsurance, residual value, and brown water marine products in the United States. The Professional Liability segment offers directors and officers (D&O) liability, large account E&O liability, fiduciary liability, fidelity and bankers blanket bonds, EPLI, transactional insurance, and cyber liability in the United States and internationally. The Accident & Health segment provides medical stop-loss, and short-term domestic and international medical coverages in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
